Peptides for Alzheimer's Disease & Cognitive Decline

How peptide Targets Peptides for Alzheimer's Disease

Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder involving amyloid-beta (Aβ) plaque deposition, hyperphosphorylated tau neurofibrillary tangles, neuroinflammation, mitochondrial dysfunction, synaptic loss, and cholinergic system degeneration. Current approved treatments — cholinesterase inhibitors (donepezil, rivastigmine) and the NMDA antagonist memantine — provide modest symptomatic benefit but do not modify disease progression. The newer anti-amyloid antibodies (lecanemab, donanemab) represent the first disease-modifying approaches but have generated debate regarding clinical significance of their effects.

Cerebrolysin has the most substantial clinical evidence among peptide approaches for AD. This neurotrophic peptide mixture has been evaluated in multiple randomized controlled trials involving AD patients. A Cochrane review and several meta-analyses have examined cerebrolysin in AD, with results showing consistent improvements in global clinical impression scores and some cognitive measures, particularly at higher doses (30 mL/day IV) over 4-week treatment courses. The magnitude of effect appears comparable to cholinesterase inhibitors. Cerebrolysin mimics the activity of neurotrophic factors (BDNF, NGF, GDNF) that are depleted in AD brain tissue, promoting neuronal survival, synaptic plasticity, and neurogenesis. It is approved for neurological conditions in over 40 countries but not approved in the US, where FDA has required additional large-scale confirmatory trials.

Dihexa is among the most potent neurotrophic peptides identified. As a hepatocyte growth factor (HGF)/c-Met receptor activator, it promotes dendritic spine formation and synaptic connectivity at remarkably low concentrations — described as up to 10 million times more potent than BDNF in stimulating dendritic connections. In animal models of cognitive impairment, dihexa restored learning and memory function. For AD, where synaptic loss is the strongest correlate of cognitive decline (stronger than plaque or tangle burden), an agent that restores synaptic connections addresses the most clinically relevant pathological feature. However, dihexa has no human clinical data and its extreme potency raises safety questions about uncontrolled neurotrophic signaling.

Mitochondrial peptides (humanin, MOTS-c, SS-31) target the metabolic crisis in AD neurons. Humanin was originally discovered as a neuroprotective factor against AD-related insults — it inhibits Aβ-induced apoptosis and has shown reduced levels in AD patients' plasma and cerebrospinal fluid. SS-31 (elamipretide) stabilizes mitochondrial function and reduces oxidative stress, which is elevated early in AD pathogenesis. MOTS-c supports cellular energy metabolism through AMPK activation. The mitochondrial dysfunction hypothesis of AD has gained traction as bioenergetic failure appears to precede amyloid deposition in some models.

Semax and selank contribute through different mechanisms: semax upregulates BDNF and modulates neurotrophic factor expression (directly relevant to AD, where BDNF is depleted), while selank addresses the anxiety and behavioral symptoms that frequently accompany AD. Pinealon, a tripeptide, has shown neuroprotective properties in cellular models of neurodegeneration. Epitalon, through telomerase activation and melatonin pathway modulation, has theoretical relevance to neuronal aging but lacks AD-specific data.

Reality check: Alzheimer's disease has been the most challenging therapeutic target in neuroscience. Hundreds of clinical trials have failed. Patients and families should be cautious about overpromising from preclinical peptide data. Standard medical management, cognitive stimulation, physical exercise, and social engagement remain the foundation of AD care.